Abstracts-highlighting-updates

HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences

TUCSON, Ariz., Dec. 06, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal ... read more

General Information about Abstracts

There are occasional joint international meetings, usually held in the host country. Sectional Meetings Require Registration to Submit Abstracts In an effort to spread the cost of the sectional ... read more

Late-breaking Abstracts and Highlights from the 2022 ASTRO Annual Meeting

Dr. Latorzeff began his presentation by highlighting that PSA persistence post-radical prostatectomy is distinct from biochemical recurrence. The Addition of Metastasis-Directed Therapy to ... read more

Exact Sciences highlights impact of precision oncology portfolio on breast cancer treatment

Exact Sciences has been presenting new data from multiple trials supporting the role of its cancer screening and diagnostic tests at the 2022 San Antonio Breast Cancer Symposium (SABCS) this month, ... read more

Jan. 20 Deadline for Abstracts for Energy HPC Conference at Ken Kennedy Institute, Rice Univ.

Friday, Jan. 20, 2023 is the deadline to submit an extended abstract for presentation at the 16th Annual 2023 Energy High Performance Computing Conference hosted by the Ken Kennedy Institute at Rice ... read more

Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX

CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment ... read more

Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX

Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of ... read more

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

today announced that four abstracts highlighting ziftomenib, the Company’s potent and selective menin inhibitor, have been accepted for presentation at the upcoming American Society of Hematology (ASH ... read more

SimBioSys® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022

SimBioSys, the precision oncology company behind the 4D Tumor Modeling™ technology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San ... read more